Clinical Trials in Nashville

Showing 4541-4560 of 20,298 trials

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

NCT05966740

The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.

Venous Thromboembolism

Boehringer Ingelheim6 participantsStarted Apr 2024

La Jolla, California, United States • San Diego, California, United States • New Haven, Connecticut, United States +7 more locations

RECRUITINGPhase 1< 1 mile

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

NCT06398418

The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

Solid Tumor, AdultSolid TumorMelanoma+3 more

Rise Therapeutics LLC33 participantsStarted Aug 2025

Nashville, Tennessee, United States

COMPLETEDPhase 2< 1 mile

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.

Acute Migraine

Kallyope Inc.431 participantsStarted Mar 2025

Birmingham, Alabama, United States • Mobile, Alabama, United States • Tucson, Arizona, United States +63 more locations

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Find Trials by Condition in Nashville

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

MR Image Synthesis With Low Gadobutrol Dose and AI

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Proton Radiation for Stage II/III Breast Cancer

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

A Study of Abemaciclib in Recurrent Glioblastoma

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM